Biosimilars engage in low levels of direct-to-physician marketing relative to reference biologics
{{output}}
Biosimilars have the potential to greatly reduce US spending on biologic drugs, but uptake of these competitor products varies. We used Open Payments data from 2014 to 2022 to proxy for direct-to-physician marketing and compared levels of activity between biol... ...
